Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women’s health in Australia and the United States. More Details
Excellent balance sheet and overvalued.
Share Price & News
How has Genetic Technologies's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GTG is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: GTG's weekly volatility has decreased from 25% to 16% over the past year, but is still higher than 75% of Australian stocks.
7 Day Return
AU Life Sciences
1 Year Return
AU Life Sciences
Return vs Industry: GTG exceeded the Australian Life Sciences industry which returned -11.1% over the past year.
Return vs Market: GTG underperformed the Australian Market which returned 35.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Genetic Technologies's share price compared to the market and industry in the last 5 years?
Simply Wall St News
4 months ago | Simply Wall StShould You Take Comfort From Insider Transactions At Genetic Technologies Limited (ASX:GTG)?
8 months ago | Simply Wall StHave Insiders Been Buying Genetic Technologies Limited (ASX:GTG) Shares?
11 months ago | Simply Wall StDo Insiders Own Lots Of Shares In Genetic Technologies Limited (ASX:GTG)?
Is Genetic Technologies undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate GTG's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate GTG's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: GTG is unprofitable, so we can't compare its PE Ratio to the XX Life Sciences industry average.
PE vs Market: GTG is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GTG's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GTG is good value based on its PB Ratio (3.8x) compared to the AU Life Sciences industry average (4.4x).
How is Genetic Technologies forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Genetic Technologies has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Genetic Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GTG is currently unprofitable.
Growing Profit Margin: GTG is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GTG is unprofitable, but has reduced losses over the past 5 years at a rate of 8.2% per year.
Accelerating Growth: Unable to compare GTG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GTG is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (38.2%).
Return on Equity
High ROE: GTG has a negative Return on Equity (-39.62%), as it is currently unprofitable.
How is Genetic Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: GTG's short term assets (A$18.1M) exceed its short term liabilities (A$1.2M).
Long Term Liabilities: GTG's short term assets (A$18.1M) exceed its long term liabilities (A$121.3K).
Debt to Equity History and Analysis
Debt Level: GTG's debt to equity ratio (0.3%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if GTG's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GTG has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: GTG has sufficient cash runway for 2.4 years if free cash flow continues to grow at historical rates of 10.8% each year.
What is Genetic Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GTG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GTG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GTG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GTG's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GTG's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Simon Morriss serves as Chief Executive Officer at Genetic Technologies Limited since February 01, 2021. Mr. Morriss brings many years’ of experience within the Pharmaceutical, Healthcare and FMCG indu...
Experienced Management: GTG's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: GTG's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 61.7%.
Genetic Technologies Limited's company bio, employee growth, exchange listings and data sources
- Name: Genetic Technologies Limited
- Ticker: GTG
- Exchange: ASX
- Founded: 1987
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$72.134m
- Shares outstanding: 9.02b
- Website: https://www.gtglabs.com
- Genetic Technologies Limited
- 60-66 Hanover Street
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women’s health in Australia and the United States. The company’s le...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/08 08:23|
|End of Day Share Price||2021/05/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.